BIOMARCADORES PARA DIAGNÓSTICO DE DEMENCIA

VolverVolver

Resultados 70 resultados LastUpdate Última actualización 30/09/2022 [12:56:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days



Página1 de 3 nextPage   por página


BIOFLUID-BASED METHODS FOR DIAGNOSING ALZHEIMER'S DISEASE-ASSOCIATED CONDITIONS

NºPublicación: WO2022197651A1 22/09/2022

Solicitante:

NEUROVISION IMAGING INC [US]

Resumen de: WO2022197651A1

This invention provides methods for determining whether a subject has a condition correlative with a matrix effect comprising (a) admixing (i) a suitably diluted sample of a suitable fluid from the subject and (ii) a suitable amount of a labeled molecule, wherein the labeled molecule is subject to a matrix effect with respect to the suitable fluid in a subject afflicted with the condition, and (b) after a suitable duration under suitable conditions, determining the amount of matrix-unaffected labeled molecule present in the resulting admixture, wherein the subject is afflicted with the condition if the amount of matrix-unaffected labeled molecule determined in step (b) correlates with a positive control for the condition, and wherein the subject is not afflicted with the condition if that amount correlates with a negative control for the condition. This invention also provides related methods, kits, and compositions. The present methods and kits are particularly useful for predicting the onset of neurodegenerative disorders such Alzheimer's disease and Parkinson's disease.

traducir

PREVENTATIVE OR THERAPEUTIC AGENT FOR TAUOPATHY

NºPublicación: US2022296548A1 22/09/2022

Solicitante:

UNIV KYOTO [JP]
NATIONAL INSTITUTES FOR QUANTUM SCIENCE AND TECH [JP]

CN_114599397_PA

Resumen de: US2022296548A1

A prophylactic or therapeutic agent for tauopathy, containing an inhibitor of α2δ of the voltage-dependent calcium channel is provided by the present invention.

traducir

COMPOSITIONS AND METHODS OF USING HisGTG TRANSFER RNAS (tRNAs)

NºPublicación: US2022298581A1 22/09/2022

Solicitante:

UNIV JEFFERSON [US]

US_2021198745_A1

Resumen de: US2022298581A1

The present invention includes a method for analyzing tRNAHisGTG fragments. In one aspect, the present invention includes a method of identifying a subject in need of therapeutic intervention to treat and/or prevent a disease or condition, disease recurrence, or disease progression comprises characterizing the identity of tRNAHisGTG fragments. The invention further includes diagnosing, identifying or monitoring a disease or condition, a panel of engineered oligonucleotides, a kit for a high-throughput assay, and a method and system for identifying tRNAHisGTG fragments.

traducir

Novel Molecules for Therapy and Diagnosis

NºPublicación: US2022298231A1 22/09/2022

Solicitante:

AC IMMUNE SA [CH]

JP_2022529344_A

Resumen de: US2022298231A1

The present invention relates to novel molecules that can be employed for the prevention, alleviation, treatment and/or diagnosis of diseases, disorders and abnormalities associated with alpha-synuclein (a-synuclein, A-synuclein, aSynuclein, A-syn, α-syn, aSyn, a-syn) aggregates, including, but not limited to, Lewy bodies and/or Lewy neurites, such as Parkinson's disease, Multiple System Atrophy, Lewy Body dementia (LBD; dementia with Lewy bodies (DLB) (“pure” Lewy body dementia), Parkinson's disease dementia (FDD)) or Diffuse Lewy Body Disease. The invention relates to alpha-synuclein binding molecules, in particular to alpha-synuclein antibodies or an antigen-binding fragment or a derivative thereof and uses thereof. The present molecules can also be used for determining a predisposition to such a disorder, disease or abnormality, monitoring residual disorder, disease or abnormality, or predicting the responsiveness of a patient who is suffering from such a disorder, disease or abnormality to treatment with a certain medicament.

traducir

METHODS TO DETECT MTBR TAU ISOFORMS AND USE THEREOF

NºPublicación: US2022299527A1 22/09/2022

Solicitante:

UNIV WASHINGTON [US]

KR_20220062287_PA

Resumen de: US2022299527A1

The methods disclosed herein employ unique combinations of processing steps that transform a blood or CSF sample into a sample suitable for quantifying MTBR tau species, as well as other tau species. The present disclosure also encompasses the use of MTBR tau species in blood or CSF to measure pathological features and/or clinical symptoms of 3R- and 4R-tauopathies in order to diagnose, stage, and/or choose treatments appropriate for a given disease stage, and modify a given treatment regimen.

traducir

COMPOSITIONS AND METHODS FOR TREATING NEUROLOGIC DISEASES

NºPublicación: WO2022197885A1 22/09/2022

Solicitante:

COGNITION THERAPEUTICS INC [US]

Resumen de: WO2022197885A1

The present disclosure relates to methods of treating neurological diseases, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound or pharmaceutical composition according to any embodiment described herein. The present disclosure relates to the methods of treating Parkinson's disease and Dementia with Lew Bodies, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound or pharmaceutical composition according to any embodiment described herein.

traducir

MODIFIED IMMUNOGLOBULINS FOR TARGETING AMYLOID DEPOSITS

NºPublicación: EP4058479A1 21/09/2022

Solicitante:

UNIV TENNESSEE RES FOUND [US]
ATTRALUS INC [US]

KR_20220113950_PA

Resumen de: WO2021097360A1

Provided herein are modified immunoglobulins comprising an amyloid reactive peptide joined to an antibody, as well as humanized antibodies that bind to human amyloid fibrils and antibody-peptide fusion proteins. Also provided herein are methods of treating amyloid-based diseases by administering a modified immunoglobulin, humanized antibody, or antibody-peptide fusion protein.

traducir

ANTI-N3PGLU AMYLOID BETA ANTIBODIES AND USES THEREOF

NºPublicación: WO2022192639A2 15/09/2022

Solicitante:

LILLY CO ELI [US]

Resumen de: WO2022192639A2

Methods of treating, preventing and / or retarding the progression of cognitive decline, in human subjects having a disease characterized by deposition of Aβ in the brain including Alzheimer's disease, Down's syndrome, and cerebral amyloid angiopathy, using anti-N3pGlu Aβ antibodies.

traducir

DETECTING EARLY STAGE NEURO-DEGENERATIVE DISEASE THROUGH OTIC CANAL OFF-GASSING

NºPublicación: WO2022192599A1 15/09/2022

Solicitante:

POSTREL RICHARD [US]

Resumen de: WO2022192599A1

The present invention teaches a system and method for the detection and identification of various neuro-degenerative diseases including, but not limited to Alzheimer's, Multiple Sclerosis, and Parkinson's Disease. This invention provides systems, methods, and devices to accurately detect neurodegenerative and/or autoimmune diseases by collecting and assaying Volatile Organic Compounds (VOCs) emitted into the otic canal, e.g., from the inner ear as gases and/or VOCs trapped in earwax. Diseases are non-invasively detected and characterized through VOC signatures unique to each disease or condition. This invention includes the use of various probes including, but not limited to those similar in shape to a conventional otoscope, standard or custom fitted earplugs, modified headgear, etc. VOCs are monitored in real-time, or in other embodiments, are captured for analysis from collected earwax or an adsorbent cartridge to permit detection of slow emission gases secreted over time, e.g., while a subject is sleeping.

traducir

METHODS FOR DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE

NºPublicación: WO2022192019A1 15/09/2022

Solicitante:

CHILDRENS MEDICAL CT CORP [US]

Resumen de: WO2022192019A1

Provided herein are methods for diagnosing and treating Alzheimer's disease in a subject comprising determining the expression level of three, four or five members of a panel of proteins in a biological sample obtained from the subject.

traducir

Anti-Tau antibodies and methods of use

NºPublicación: AU2022209213A1 15/09/2022

Solicitante:

AC IMMUNE SA [CH]
GENENTECH INC [US]

TW_202212356_PA

Resumen de: AU2022209213A1

The invention provides anti-Tau antibodies and methods of using the same.

traducir

MUCIN ISOFORMS IN DISEASES CHARACTERIZED BY BARRIER DYSFUNCTION

NºPublicación: US2022291233A1 15/09/2022

Solicitante:

UNIV ANTWERPEN [BE]

CN_114502189_PA

Resumen de: US2022291233A1

The present invention relates to the field of mucin isoforms, more in particular for use in the diagnosis, monitoring, prevention and/or treatment of a disease characterized by barrier dysfunction, such as but not limited to a gastrointestinal disorder (e.g. Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), cancer, gastro-intestinal infections, obesitas, non-alcoholic fatty liver disease (NAFLD)), neurodegenerative disorders, respiratory infections, . . . In a specific embodiment, said mucin isoform is selected from the list comprising: MUC1 isoforms and MUC13 isoforms.

traducir

COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES

NºPublicación: US2022288151A1 15/09/2022

Solicitante:

CARMEL HAIFA UNIV ECONOMIC CORPORATION LTD [IL]

WO_2021024258_A1

Resumen de: US2022288151A1

The present invention relates to a method for treating a neurological disease in a subject including administering to the subject a pharmaceutical composition of a eukaryotic elongation factor 2 kinase (eEF2K)-inhibiting compound.

traducir

CLEARANCE ASSAY

NºPublicación: WO2022189463A1 15/09/2022

Solicitante:

AKERSHUS UNIV HF [NO]

Resumen de: WO2022189463A1

An ex vivo method of determining the effect of an agent on catalysis by a Monocyte Phagocyte System (MPS) cell of a disease marker product and/or at least one fragment thereof associated with neurodegeneration and/or inflammatory activation. The method comprises: i) maintaining a sample of MPS cells under conditions in which the MPS cells remain alive, ii) exposing the sample of MPS cells to an agent and a disease marker product, to permit phagocytosis of the disease marker product by the MPS cells, iii) detecting the intracellular amount of the disease marker product and/or at least one fragment thereof in the sample of MPS cells, and iv) comparing the intracellular amount of the disease marker product and/or the at least one fragment thereof to an intracellular amount of the same disease marker product and/or at least one fragment thereof measured in control MPS cells in the absence of the agent. The effect of the agent on catalysis by MPS cells of the disease marker product and/or at least one fragment thereof is determined by the result of the comparison of step iv).

traducir

ANTI-AMYLOID BETA ANTIBODIES AND USES THEREOF

NºPublicación: WO2022192636A1 15/09/2022

Solicitante:

LILLY CO ELI [US]

Resumen de: WO2022192636A1

The invention is directed to treatment or prevention of a disease characterized by deposition of Aβ in the brain using anti-Aβ antibodies. The diseases that can be treated or prevented include, e.g., Alzheimer's disease, Down's syndrome, and cerebral amyloid angiopathy. The invention is also related to, in some aspects, to selecting a human subject based on the tau burden in the human subjects' brain, who is responsive to treatment or prevention of a disease characterized by deposition of Aβ in the brain that includes administering anti-Aβ antibodies. The invention is also related to human subjects who have one or two alleles of APOE e4.

traducir

METHOD FOR ASSISTING WITH DIAGNOSIS OF ALZHEIMER'S DISEASE OR MILD COGNITIVE IMPAIRMENT, BIOMARKER, REAGENT KIT, AND DEVICE

NºPublicación: US2022291242A1 15/09/2022

Solicitante:

FUJIFILM WAKO PURE CHEMICAL CORP [JP]
FUJIFILM WAKO SHIBAYAGI CORP [JP]

WO_2021107154_A1

Resumen de: US2022291242A1

A method for assisting the diagnosis of Alzheimer's disease, comprising: measuring an amount of extracellular vesicles having phosphatidylserine and tetraspanin, or the amount of extracellular vesicles having phosphatidylserine and tetraspanin and an amount of extracellular vesicles having tetraspanin, in a biological specimen derived from a subject; and determining that the subject has Alzheimer's disease using the amount of extracellular vesicles having phosphatidylserine and tetraspanin, or a ratio of the amount of extracellular vesicles having phosphatidylserine and tetraspanin to the amount of extracellular vesicles having tetraspanin as an indicator.

traducir

USE OF TROPOMYOSIN ALPHA-4 CHAIN AND PLATELET GLYCOPROTEIN IB BETA CHAIN FOR DIAGNOSIS OF ALZHEIMER'S DISEASE

NºPublicación: KR20220125640A 14/09/2022

Solicitante:

주식회사피플바이오

WO_2022186486_PA

Resumen de: WO2022186486A1

The present invention relates to a composition and a diagnostic kit for the diagnosis of Alzheimer's disease, and a method for providing information needed for diagnosing Alzheimer's disease by using the composition and the kit. TPM4, GP1BB, or a combination thereof, which are biomarkers in plasma that were newly developed by the inventors of the present invention, is expressed at a low level in the plasma of an Alzheimer's disease patient group as compared to normal individuals, and thus, through measurement of the expression levels of the biomarkers, whether or not a patient has Alzheimer's disease can be accurately diagnosed early.

traducir

SYSTEM AND METHOD FOR PROTEIN CORONA SENSOR ARRAY FOR EARLY DETECTION OF DISEASES

NºPublicación: EP4056263A1 14/09/2022

Solicitante:

THE BRIGHAM & WOMENS HOSPITAL INC [US]

ES_2914787_T3

Resumen de: EP4056263A1

The present disclosure provides sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.

traducir

Test strip and method for detecting urine A beta amyloid protein

NºPublicación: JP2022539580A 12/09/2022

Solicitante:

湖南乾康科技有限公司

AU_2019470252_PA

Resumen de: CN111656197A

The invention discloses a test strip and method for detecting urine A beta amyloid protein. The test strip for detecting the urine A beta amyloid protein comprises a PVC bottom plate (7), wherein a sample pad (1), a conjugated pad (2), a chromatography pad (3) and a water absorption pad (4) which are sequentially overlapped are paved on the PVC bottom plate (7); the conjugated pad (2) is coated with colloidal gold particles conjugated with a monoclonal antibody; a detection line (5) is arranged on one side, close to the conjugated pad (2), of the chromatography pad (3); a contrast control line(6) is arranged on one side, close to the water absorption pad (4), of the chromatography pad (3); the detection line (5) is coated with an A beta amyloid protein binding polymer; and the contrast control line (6) is coated with a goat anti-mouse IgG polyclonal antibody. The method is high in sensitivity, has a detection limit of 40 pg, is rapid and economical, is suitable for conventional clinical pathological examination, is suitable for general screening of a large number of people and self-screening of home terminal users, is especially used for clinically assisting early diagnosis and pre-judgment of mild cognitive impairment (MCI), and predicts and judges whether a patient has high risk of developing MCI and AD.

traducir

USE OF TROPOMYOSIN ALPHA-4 CHAIN AND PLATELET GLYCOPROTEIN IB BETA CHAIN FOR DIAGNOSIS OF ALZHEIMER'S DISEASE

NºPublicación: WO2022186486A1 09/09/2022

Solicitante:

PEOPLEBIO INC [KR]

KR_20220125640_PA

Resumen de: WO2022186486A1

The present invention relates to a composition and a diagnostic kit for the diagnosis of Alzheimer's disease, and a method for providing information needed for diagnosing Alzheimer's disease by using the composition and the kit. TPM4, GP1BB, or a combination thereof, which are biomarkers in plasma that were newly developed by the inventors of the present invention, is expressed at a low level in the plasma of an Alzheimer's disease patient group as compared to normal individuals, and thus, through measurement of the expression levels of the biomarkers, whether or not a patient has Alzheimer's disease can be accurately diagnosed early.

traducir

PERSONALIZED MEDICINE APPROACH FOR TREATING COGNITIVE LOSS

NºPublicación: WO2022187670A1 09/09/2022

Solicitante:

UNIV OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH [US]

Resumen de: WO2022187670A1

The present disclosure relates to a method of treating a subject having a proinflammatory endophenotype profile with celecoxib or naproxen to improve cognition or to prevent cognitive decline or dysfunction in the subject. In another aspect, the present disclosure relates to a method of screening a subject for inclusion an NSAID or a PPAR-γ agonist clinical trial. In another aspect, the present disclosure relates to a method of determining a surrogate outcome of an NSAID or a PPAR-γ agonist clinical trial. In yet another aspect, the present disclosure relates to a method of treating an Alzheimer's disease patient having both a proinflammatory endophenotype profile and a metabolic endophenotype profile with a PPAR-γ agonist to improve cognition or to prevent cognitive decline or dysfunction in the patient.

traducir

COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE OR OTHER NEURODEGENERATIVE DISORDERS

NºPublicación: WO2022187678A1 09/09/2022

Solicitante:

UNIV DUKE [US]
THE US GOV AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS [US]
SUHOCKI PAUL V [US]
DORAISWAMY PUDUGRAMAM MURALI [US]

Resumen de: WO2022187678A1

Described herein are compositions and method for the diagnosis and treatment of Alzheimer's disease or other neurodegenerative disorders, in one embodiment, the composition augments a subject's gut microbial flora and reduces one or more biomarkers associated with Alzheimer's Disease. In one aspect, the composition comprises one or more bacteria species selected from Lactobacillus, Erysipelatociostridium, Faecalitalea, Erysypeiotrichaceae, Anaerostipes, Blautia, Ruminiclostridium, or combinations thereof and one or more pharmaceutically acceptable excipients.

traducir

TDP-43 IN DEGENERATIVE DISEASE

NºPublicación: US2022283180A1 08/09/2022

Solicitante:

UNIV JOHNS HOPKINS [US]

Resumen de: US2022283180A1

Chimeric proteins comprising an N-terminal domain derived from an N-terminal nucleotide binding domain of TDP-43 and a C-terminal domain derived from a splicing repressor are described. These proteins may be administered to a subject to treat or prevent disease manifesting TDP-43 proteinopathy such as inclusion body myocytosis, amyotrophic lateral sclerosis (ALS), or frontotemporal dementia (FTD).

traducir

ASSAYS FOR DETECTING AND QUANTIFYING A BIOMARKER OF PERICYTE INJURY

NºPublicación: US2022283185A1 08/09/2022

Solicitante:

UNIV SOUTHERN CALIFORNIA [US]

WO_2021041731_A1

Resumen de: US2022283185A1

A highly sensitive immunoassay has been developed and validated. In various embodiments, the assay comprises an immunoassay usable to measure soluble PDGFRβ (sPDGFR-β) in a human biofluid sample such as cerebrospinal fluid (CSF). In various embodiments, elevated sPDGFR-β in a human biofluid sample reflects pericyte and blood-brain barrier (BBB) injury, and is therefore an early biomarker of human cognitive dysfunction, dementia, and/or Alzheimer's disease.

traducir

TARGETING LIGANDS FOR TAU PATHOLOGY

Nº publicación: US2022283187A1 08/09/2022

Solicitante:

ALZECA BIOSCIENCES LLC [US]
TEXAS CHILDRENS HOSPITAL [US]

Resumen de: US2022283187A1

Methods and compositions for detecting tau pathology are described. The compositions for detecting tau pathology comprise a targeting ligand that specifically binds to a cell surface marker of tau pathology, wherein the targeting ligand is linked to a liposome that includes an imaging agent. The compositions can be used in a method for imaging tau pathology in a subject that comprises administering to the subject an effective amount of the composition to a subject and imaging at least a portion of the subject to determine if that portion of the subject exhibits tau pathology. The compositions can also be used to detect tau pathology in biological samples obtained from a subject.

traducir

Página1 de 3 nextPage por página

punteroimgVolver